Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

December 01, 1995; 45 (12 Suppl 8) Updated Proceedings of the Second International Conference on the Varicella-Zoster Virus

Immunization to reduce the frequency and severity of herpes zoster and its complications

Michael N. Oxman
First published December 1, 1995, DOI: https://doi.org/10.1212/WNL.45.12_Suppl_8.S41
Michael N. Oxman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Immunization to reduce the frequency and severity of herpes zoster and its complications
Michael N. Oxman
Neurology Dec 1995, 45 (12 Suppl 8) S41-S46; DOI: 10.1212/WNL.45.12_Suppl_8.S41

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
67

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Herpes zoster (HZ) is a localized disease that results from reactivation of an endogenous varicella-zoster virus (VZV) infection that has persisted in latent form within sensory ganglia following an earlier attack of varicella. The incidence and the severity of HZ and its complications increase with advancing age, and this is temporally associated with an age-related decline in cell-mediated immunity (CMI) to VZV. Information on the cellular site and mechanism of VZV latency and on the events that follow reactivation appears to explain many of the clinical features of HZ and to provide a pathophysiologic basis for the presumption that immunity to VZV plays a critical role in limiting the frequency and consequences of VZV reactivation. The close temporal correlation between the decline in VZV-specific CMI and the increased frequency and severity of HZ and its complications in older individuals suggests that HZ may actually develop because VZV-specific CMI falls below some critical threshold. The development of a live attenuated varicella vaccine provides a means of stimulating VZV-specific CMI and thus of determining its role in the pathogenesis of HZ. Levin and his colleagues have demonstrated that waning VZV-specific CMI in elderly persons can be stimulated by varicella vaccine to levels typical of those observed in younger persons, in whom the incidence and severity of HZ are much reduced. Thus the stage is set for a large placebo-controlled clinical trial that will test directly the hypothesis that restoration of waning CMI to VZV will reduce the frequency and severity of HZ and its complications in the elderly.

NEUROLOGY 1995;45(Suppl 8): S41-S46

The past three decades have seen herpes zoster (HZ) research reach a significant threshold. Investigators are now in a position to determine whether immunization can reduce the incidence and/or severity of HZ and its complications. Such a determination will, at last, provide a test of Edgar Hope-Simpson's prescient hypothesis [1] that the occurrence of HZ is determined by host immunity to varicella-zoster virus (VZV). Summarized below are some of the important observations that provide a rationale for this approach to the prevention of HZ and its complications.

HZ is a localized disease characterized by unilateral radicular pain and a vesicular cutaneous eruption that is generally limited to the dermatome innervated by a single spinal or cranial sensory ganglion. It results from reactivation of an endogenous VZV infection that has persisted in a latent form within the sensory ganglia following an earlier attack of varicella. [1,2] Both the incidence and the severity of HZ increase with advancing age, and complications, which are rare in normal children and younger adults, occur in almost one-half of older individuals. [1-4] The most frequent complication of HZ in older individuals is postherpetic neuralgia (PHN), a syndrome of pain, allodynia, dysesthesia, and hyperesthesia that persists or develops after the dermatomal rash has healed. PHN can be prolonged and disabling, and its frequency and severity also increase with advancing age.

Pathogenesis of HZ: the role of host immunity.

Hope-Simpson proposed that host immunity controls reactivation of latent VZV and limits the spread of reactivated virus within the ganglion and from the ganglion to the skin. He hypothesized that HZ occurs when VZV-specific immunity falls below some critical threshold Figure 1. [1] He suggested that this immunity declines as a consequence of the aging process itself but may be boosted periodically by exogenous exposure to children with varicella, as well as by endogenous exposure to VZV antigens produced during episodes of ganglionic reactivation that are contained by host immune responses ("contained reversions'') and thus do not result in HZ. He also hypothesized that HZ itself induces a marked increase in immunity to VZV and that this explains the rarity of second episodes of HZ.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Pathogenesis of herpes zoster. (Modified, with permission, from Figure 1 in reference 2, which was based on the original by Hope-Simpson. [1])

Most of the elements of Hope-Simpson's remarkable hypothesis have since been validated. Endogenous reactivation in the absence of rash has been documented and has been shown to boost cell-mediated immunity (CMI) to VZV, and HZ itself has been demonstrated to markedly increase VZV-specific CMI. [5-9] Exogenous reexposure resulting from contact with children with varicella has also been shown to boost humoral immunity and CMI to VZV. [10,11] Finally, a marked decline in host immunity with advancing age has been documented by a number of investigators [9,11-16] Figure 2. In fact, the only aspect of our current understanding not encompassed by Hope-Simpson's model is the recognition that it is VZV-specific CMI rather than humoral immunity that is critical in limiting the occurrence of HZ and its complications. [9,11-16]

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Age-related decline in VZV-specific cell-mediated immunity. PHA equals phytohemagglutinin. (Modified, with permission, from Burke et al, Arch Intern Med 1982;142:291-293. [14] Copyright 1982, American Medical Association.)

Ganglionic latency: VZV versus herpes simplex virus.

Virus-specific CMI also plays an important role in the pathogenesis of recurrent herpes simplex virus (HSV) infections, but differences in the cellular sites and mechanisms of HSV and VZV latency appear to dictate important differences in the pathophysiology of reactivation and the characteristics of the resulting diseases Table 1. These differences have important implications for the potential efficacy of immunologic interventions.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1. Herpes zoster versus recurrent herpes simplex

Aided by the availability of excellent animal models, a number of investigators have identified the sensory neuron as the ganglionic site of HSV latency (reviewed by Fraser et al [17]). Furthermore, during HSV latency, transcription is limited to only one small region of the viral genome, resulting in a set of latency-associated transcripts that overlap the 3 prime end of one of the immediate early HSV genes (ICPO) in an antisense manner. Latency-associated transcripts are not polyadenylated and remain confined to the cell nucleus, and there does not appear to be any HSV-encoded protein synthesized in latently infected neurons. Recent studies by Straus and his colleagues [18] indicate that the site of VZV latency is not the sensory neuron but the satellite cells that surround it. Moreover, in contrast to HSV, polyadenylated messenger RNAs corresponding to several of the immediate early and early genes of VZV are transcribed in the latently infected satellite cells. These anatomic and molecular biologic differences provide a possible explanation for many of the differences between the natural history of HZ and that of recurrent HSV Table 1.

Biologic implications of the site and nature of viral latency.

Herpes simplex virus.

The site of latency itself has a number of important implications. In the case of HSV, the latently infected neuron extends its axon to the skin. Thus, while the mechanisms involved are unknown, it is not surprising that cutaneous stimuli such as ultraviolet light can alter neuronal physiology and result in reactivation of latent virus. Moreover, the newly reactivated HSV has direct intra-axonal access to the skin, without any requirement for replication or spread to other cells within the ganglion. This is consistent with the brief and mild (frequently absent) prodrome, the involvement of only a very small portion of the dermatome (typically the sensory field of a single neuron), the absence of significant ganglionic pathology, and the extreme rarity of PHN. Direct access to the periphery also facilitates asymptomatic virus shedding, which is responsible for most of the person-to-person spread of HSV. Moreover, since access to the skin does not require horizontal spread of HSV within the ganglion, neuronal reactivation need not involve a fully productive lytic infection. This is consistent with the apparent survival of latently infected neurons following reactivation, a phenomenon required to explain the common occurrence of multiple episodes of recurrent herpes simplex at the same cutaneous site with no sensory loss or other neurologic residua. Finally, the apparent absence of HSV-encoded proteins in latently infected neurons makes it difficult to envision a mechanism by which virus-specific CMI can limit neuronal reactivation. Host immune responses do, however, affect the subsequent replication of virus in the skin, preventing or limiting the extent of the resulting lesions. Immune responses may even reduce the amount of virus shed during periods of asymptomatic virus shedding.

Varicella-zoster virus.

In contrast to HSV, VZV is latent in satellite cells, which have no direct link with the periphery. When virus reactivates, it must initiate a productive lytic infection and spread to other cells within the ganglion in order to infect neurons and thereby gain access to the skin. This is reflected, in the majority of cases, by a prolonged prodrome of unilateral segmental neuritis that is often very painful and which is followed by the development of a vesicular rash that involves a large portion of the dermatome, corresponding to the sensory fields of the many neurons within the ganglion that are infected. The passage of small quantities of VZV from the infected ganglion into the bloodstream explains the frequent occurrence of a few vesicles at a distance from the involved dermatome in patients with uncomplicated HZ, a phenomenon that is not observed in immunocompetent persons with recurrent HSV infections. The productive lytic infection of numerous cells within the ganglion and the inflammatory response that this elicits result in hemorrhagic necrosis with neuronal loss and subsequent fibrosis. [19-22] The process often extends centrally, resulting in meningeal inflammation and involving second-order sensory neurons and sometimes motor neurons in the spinal cord or brainstem. [19-22]

These events and the pathology that they produce provide the substrate for many of the complications of HZ, particularly PHN [21,22] Table 2. Furthermore, since satellite cells have no direct connection to the skin, it is not surprising that peripheral stimuli such as ultraviolet light are unable to reactivate latent VZV. The lack of any direct connection between the latently infected satellite cells and the periphery also helps to explain the absence of asymptomatic shedding of VZV.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 2. Complications of herpes zoster

The potential role of virus-specific CMI in controlling VZV latency and reactivation.

Two features of VZV latency and reactivation, in particular, suggest an important role for host immunity in limiting the frequency and severity of HZ and its complications. Several immediate early and early VZV genes appear to be expressed during latency, and this may permit latently infected cells to be "recognized'' by the host's immune system. Consequently, VZV-specific immune responses may play a direct role in limiting reactivation itself. When reactivation does occur, the requirement for virus replication and spread within the ganglion provides ample opportunity for host immune responses to halt the process before the skin is involved, and this is almost certainly the explanation for zoster sine herpete, as well as for episodes of asymptomatic reactivation detectable only by the resulting boost in VZV-specific immune responses. [5-8,22-24] These considerations support the supposition that the marked increase in the frequency and severity of HZ and its complications observed in elderly persons [1-4] Figure 3 is caused by the age-related decline in CMI to VZV Figure 2. [12-15]

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 3. Incidence of herpes zoster versus age. (Reprinted, with permission, from Ragozzino et al, Medicine 1982;61:310-316. [3])

Therapeutic implications.

Given these observations, what can be done to reduce the frequency and severity of HZ and PHN in older persons? One approach is to inhibit VZV replications as soon as possible after the rash of HZ has appeared by the prompt administration of antiviral agents. However, while antiviral therapy can speed the resolution of the rash and may also affect the duration of PHN, such treatment is unlikely to eliminate this complication because many of the pathologic changes responsible for PHN will already have occurred before the rash appears. The best hope of reducing the incidence of HZ and its complications, particularly PHN, lies in preventing reactivation itself, or at least blocking the subsequent replication and spread of reactivated virus within the ganglion, events that precede the development of the cutaneous eruption. The recently licensed live attenuated Oka/Merck varicella vaccine offers the possibility of accomplishing this goal by boosting immunity to VZV in elderly persons.

Immunization: live attenuated varicella vaccine.

In the early 1970s, Takahashi et al [25] isolated a strain of VZV from a Japanese child with varicella and attenuated it by serial passage in human and guinea pig cells. This vaccine and derivatives of it (eg, the Oka/Merck strain) induce VZV-specific humoral immunity and CMI in normal and immuno-compromised children and in normal adults who are susceptible to VZV. [9,11,16,25-34] The vaccine is clearly attenuated [32] and has not been associated with significant side effects in normal vaccinees. [16,25-34] In addition, these vaccines have been shown to boost VZV-specific CMI when administered to seropositive elderly adults. [9,16,33-38] Levin et al [16,35] have immunized more than 200 seropositive elderly adults (mean age equals approximately 67 years) with live attenuated Oka/Merck varicella vaccine. The vaccine was well tolerated and the majority of recipients exhibited a significant boost in VZV-specific cellular immunity, as indicated by an increase in VZV-specific responder cell frequency from a prevaccination mean below 1/70,000 (1.4 responder cells per 105 peripheral blood mononuclear cells [PBMC]) to a mean of approximately 1/40,000 (2.5 responder cells per 105 PBMC) 6 months after vaccination Figure 4, a response comparable to that induced by an episode of HZ. [9,16] The level of VZV-specific CMI achieved by vaccination is typical of that observed in 40-year-old individuals, in whom the incidence and severity of HZ is markedly reduced.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 4. VZV-specific cell-mediated immune response of elderly subjects to live attenuated Oka/Merck varicella vaccine. Vaccine administered on day 0 (based upon data in reference 35). PBMC equals peripheral blood mononuclear cells.

The boost in VZV-specific cellular immunity induced by varicella vaccine was long-lasting, having a half-life of 54 months. [35] During more than 4 years of observation representing more than 800 patient-years, eight episodes of dermatomal pain, skin lesions, or both were reported in vaccine recipients. Only one was virologically confirmed and two were immunologically confirmed as HZ, and none were associated with prolonged pain, extensive rash, or PHN. [35]

Immunization to reduce the frequency and severity of HZ.

The finding of an age-related decrease in VZV-specific CMI Figure 2 and the observation that the incidence and severity of HZ and its complications are increased in elderly and immunocompromised persons [1,3,4] Figure 3, taken together, raise the obvious question of whether this association is causal or merely coincidental. The availability of a safe and effective live attenuated varicella vaccine capable of boosting VZV-specific CMI in elderly seropositive individuals offers an opportunity to answer this question. However, because of the relatively low annual incidence of HZ and PHN, and because of the impracticality of a postimmunization surveillance period much longer than 3 years in elderly subjects, the answer can be obtained only by means of a large, prospective, placebo-controlled clinical trial.

The protocol for such a trial, involving a total of 27,000 subjects 60 years of age or older randomized to receive either vaccine or placebo and then actively followed for a minimum of 3 years, has been developed in collaboration with Merck and Company and approved by the Veterans Administration Cooperative Studies Program. With a total of 160 to 240 cases of HZ and 30 to 50 cases of PHN expected to occur in the placebo group, this study should provide a definitive answer to the question of whether immunization can reduce the frequency and/or severity of HZ and PHN. It should also provide the first real test of Hope-Simpson's hypothesis that host immunity is the primary determinant of the incidence and severity of HZ and its complications.

  • Copyright 1995 by Advanstar Communication Inc.

REFERENCES

  1. 1.↵
    Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965;58:9-20.
    OpenUrlPubMed
  2. 2.
    Oxman MN. Herpes zoster, chapter 236. In: Braude AI, Davis CE, Fierer J, eds. Infectious diseases and medical microbiology. International textbook of medicine. 2nd ed.
  3. 3.↵
    Ragozzino MW, Melton LJ III, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine 1982;61:310-316.
    OpenUrl
  4. 4.
    Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995;155:1605-1609.
    OpenUrl
  5. 5.↵
    Luby JP, Ramierez-Ronda C, Rinner S, Hull A, Vergne-Marini P. A longitudinal study of varicella-zoster virus infections in renal transplant recipients. J Infect Dis 1977;135:659-663.
    OpenUrl
  6. 6.
    Gershon A, Steinberg W, Borkowsky D, Lennette D, Lennette E. IgM to varicella-zoster virus; demonstration in patients with and without clinical zoster. Pediatr Infect Dis 1982;1:164-167.
    OpenUrl
  7. 7.
    Ljungman P, Lonnqvist B, Gahrton G, Ringden O, Sundqvist VA, Wahren B. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis 1986;153:840-847.
    OpenUrlAbstract/FREE Full Text
  8. 8.
    Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 1992;165:119-126.
    OpenUrlFREE Full Text
  9. 9.↵
    Hayward A, Levin M, Wolf W, Angelova G, Gilden D. Varicella-zoster virus-specific immunity after herpes zoster. J Infect Dis 1991;163:873-875.
    OpenUrl
  10. 10.↵
    Arvin AM, Koropchak CM, Wittek AE. Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis 1983;148:200-205.
    OpenUrl
  11. 11.
    Arvin AM. Cell-mediated immunity to varicella-zoster virus. J Infect Dis 1992;166(suppl 1):S35-S41.
  12. 12.↵
    Miller AE. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 1980;30:582-587.
    OpenUrl
  13. 13.
    Berger R, Florent G, Just M. Decrease of the lymphoprolifer-ative response to varicella-zoster virus antigen in the aged. Infect Immun 1981;32:24-27.
    OpenUrl
  14. 14.↵
    Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune responses to varicella-zoster virus antigen in the aged. Arch Intern Med 1982;142:291-293.
    OpenUrl
  15. 15.
    Hayward AR, Herberger M. Lymphocyte responses to varicella zoster virus in the elderly. J Clin Immunol 1987;7:174-178.
    OpenUrlPubMed
  16. 16.↵
    Levin MJ, Murray M, Rotbart HA, Zerbe GO, White CJ, Hayward AR. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992;166:253-259.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Fraser NW, Spivack JG, Wroblewska Z, et al. A review of the molecular mechanisms of HSV-1 latency. Curr Eye Res 1991;10:1-13.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    Meier JL, Straus SE. Comparative biology of latent varicella-zoster virus and herpes simplex virus infections. J Infect Dis 1992;166:S13-S23.
    OpenUrl
  19. 19.↵
    Head H, Campbell AW. The pathology of herpes zoster and its bearing on sensory localization. Brain 1900;23:353.
    OpenUrl
  20. 20.
    Denny-Brown D, Adams RD, Fitzgerald PJ. Pathologic features of herpes zoster: a note on "geniculate herpes.'' Arch Neurol Psychiatr 1944;51:216.
  21. 21.↵
    Watson CPN, Deck JH, Morshead C, Van der Kooy D, Evans RJ. Postherpetic neuralgia: further post-mortem studies of cases with and without pain. Pain 1991;44:105-117.
    OpenUrl
  22. 22.
    Oxman MN, Alani R. Varicella and herpes zoster. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, eds. Dermatology in general medicine. 4th ed. New York: McGraw-Hill, 1993:2543-2572.
  23. 23.
    Easton HG. Zoster sine herpete causing trigeminal neuralgia. Lancet 1970;2:1065.
    OpenUrlPubMed
  24. 24.
    Lewis GW. Zoster sine herpete. Br Med J 1958;2:418.
    OpenUrl
  25. 25.↵
    Takahaski M, Otsuka T, Okuna Y, Asano Y, Yazaki T, Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2:1288-1290.
    OpenUrlPubMed
  26. 26.
    Asano Y, Nagai T, Miyata T. Long-term protective immunity of recipients of the OKA strain of a live varicella vaccine. Pediatrics 1985;75:667-671.
    OpenUrl
  27. 27.
    Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med 1984;310:1409-1415.
    OpenUrlCrossRefPubMed
  28. 28.
    Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 1986;78:748-756.
    OpenUrl
  29. 29.
    Gershon AA, Steinberg SP, LaRussa P, et al. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 1988;158:132-137.
    OpenUrlFREE Full Text
  30. 30.
    Hardy IRB, Gershon AA. Prospects for use of a varicella vaccine in adults. Infect Dis Clin North Am 1990;4:159-173.
    OpenUrlPubMed
  31. 31.
    Diaz PS, Smith S, Hunter E, Arvin AM. T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol 1989;142:636-641.
    OpenUrl
  32. 32.↵
    Tsolia M, Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Pediatr 1990;116:184-189.
    OpenUrlCrossRefPubMed
  33. 33.
    Takahashi M, Iketani T, Sasada K, et al. Immunization of the elderly and patients with collagen vascular diseases with live varicella vaccine and use of varicella skin antigen. J Infect Dis 1992;166:58-62.
    OpenUrl
  34. 34.
    Gershon AA, LaRussa P, Hardy I, Steinberg S, Silverstein S. Varicella vaccine: the American experience. J Infect Dis 1992;166:63-68.
    OpenUrl
  35. 35.↵
    Levin MJ, Murray M, Zerbe GO, White CJ, Hayward AR. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis 1994;170:522-526.
    OpenUrl
  36. 36.
    Berger R, Luescher D, Just M. Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. J Infect Dis 1984;149:647.
    OpenUrl
  37. 37.
    Berger R, Amstutz I, Just M, Just V, Luescher D. Booster vaccination of healthy adults with VZV antibody but without a VZV-specific cell-mediated immune response. Antiviral Res 1985;1(suppl 1):267-271.
  38. 38.
    Starr SE, Tinklepaugh C, Bocks E, et al. Immunization of healthy seropositive middle-aged and elderly adults with varicella-zoster virus (VZV) vaccine. Presented at the 27th Interscience Conference on Antimicrobial Agent??? and Chemotherapy; autumn 1987; New York, NY.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Pathogenesis of HZ: the role of host immunity.
    • Ganglionic latency: VZV versus herpes simplex virus.
    • Biologic implications of the site and nature of viral latency.
    • The potential role of virus-specific CMI in controlling VZV latency and reactivation.
    • Therapeutic implications.
    • Immunization: live attenuated varicella vaccine.
    • Immunization to reduce the frequency and severity of HZ.
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Clinical and Ethical Challenges
    The challenging patient with varicella-zoster virus disease
    Maria A. Nagel, Don Gilden et al.
    Neurology: Clinical Practice, April 15, 2013
  • Articles
    Varicella zoster virus vasculopathy
    Analysis of virus-infected arteries
    M.A. Nagel, I. Traktinskiy, Y. Azarkh et al.
    Neurology, July 13, 2011
  • Article
    Varicella zoster virus–infected cerebrovascular cells produce a proinflammatory environment
    Dallas Jones, C. Preston Neff, Brent E. Palmer et al.
    Neurology: Neuroimmunology & Neuroinflammation, July 18, 2017
  • Article
    Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis
    Don Gilden, Teresa White, Nelly Khmeleva et al.
    Neurology, February 18, 2015
Neurology: 100 (12)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise